Literature DB >> 35859262

Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer.

Ji-Li Xu1.   

Abstract

BACKGROUND: The molecular driving forces of anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC) remain unclear, which causing great difficulty in identifying an appropriate treatment strategy. AIMS: This study aims to explore the associations between expression of Wilms tumor 1-associated protein (WTAP) and effector T-cell infiltration in PDAC.
METHODS: In this study, we explored the association between WTAP expression and infiltration level of CD8+ T cells in PDAC. 178 PDAC samples were selected from The Cancer Genome Atlas (TCGA) database. The associations between diverse immune-cell infiltration, Tumor Mutation Burden (TMB), immune checkpoints, and WTAP expression were performed via R software. Transcriptional hallmarks of anti-tumor immunity and known T-cell-inflamed signature of PDAC were both selected to explore the relevance to WTAP expression. Potential immune checkpoint blockade (ICB) response to different WTAP expression was predicted with tumor immune dysfunction and exclusion (TIDE) algorithm.
RESULTS: WTAP was closely linked to CD8+ T-cell infiltration (r ≥ 0.5, P value < 0.05) and did not show notable association with TMB in PDAC. WTAP positively linked to T-cell-inflamed gene expression profiles (GEP) (IL2RB, IL2RA, ZAP70, ITK, CD3E, CD38, CD27, CD276, CD8A, CMKLR1, CXCR6, HLA-DQA1, HLA-DRB1, HLA-E, NKG7, and STAT1), cytolytic activity (GZMA and PRF1), various immune checkpoints (IDO1, CD274, HAVCR2, PDCD1, CTLA4, LAG3, and PDCD1LG2) and 4-chemokine signature (CCL4, CCL5, CXCL9, and CXCL10). Besides, increased expression of WTAP was related to a higher TIDE score.
CONCLUSIONS: WTAP marks PDAC tumors with an active anti-tumor phenotype and might help the identification of PDAC patients who might benefit from immunotherapies.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Immune checkpoint; Immunotherapy; PDAC; T-cell-inflamed; WTAP

Year:  2022        PMID: 35859262     DOI: 10.1007/s10620-022-07620-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  44 in total

1.  Identification of WTAP, a novel Wilms' tumour 1-associating protein.

Authors:  N A Little; N D Hastie; R C Davies
Journal:  Hum Mol Genet       Date:  2000-09-22       Impact factor: 6.150

2.  Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells.

Authors:  R Desrosiers; K Friderici; F Rottman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

Review 3.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

Authors:  Priti S Hegde; Vaios Karanikas; Stefan Evers
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

4.  Wilms' tumor 1-associating protein regulates G2/M transition through stabilization of cyclin A2 mRNA.

Authors:  Keiko Horiuchi; Michihisa Umetani; Takashi Minami; Hiroto Okayama; Shinji Takada; Masayuki Yamamoto; Hiroyuki Aburatani; Patrick C Reid; David E Housman; Takao Hamakubo; Tatsuhiko Kodama
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

5.  Global Burden of 5 Major Types of Gastrointestinal Cancer.

Authors:  Melina Arnold; Christian C Abnet; Rachel E Neale; Jerome Vignat; Edward L Giovannucci; Katherine A McGlynn; Freddie Bray
Journal:  Gastroenterology       Date:  2020-04-02       Impact factor: 22.682

6.  Identification of Wilms' tumor 1-associating protein complex and its role in alternative splicing and the cell cycle.

Authors:  Keiko Horiuchi; Takeshi Kawamura; Hiroko Iwanari; Riuko Ohashi; Makoto Naito; Tatsuhiko Kodama; Takao Hamakubo
Journal:  J Biol Chem       Date:  2013-10-07       Impact factor: 5.157

7.  T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.

Authors:  Jonathan A Trujillo; Randy F Sweis; Riyue Bao; Jason J Luke
Journal:  Cancer Immunol Res       Date:  2018-09       Impact factor: 11.151

8.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 9.  Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.

Authors:  Prashanth Rawla; Tagore Sunkara; Vinaya Gaduputi
Journal:  World J Oncol       Date:  2019-02-26

10.  WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.

Authors:  Yunhao Chen; Chuanhui Peng; Junru Chen; Diyu Chen; Beng Yang; Bin He; Wendi Hu; Yanpeng Zhang; Hua Liu; Longfei Dai; Haiyang Xie; Lin Zhou; Jian Wu; Shusen Zheng
Journal:  Mol Cancer       Date:  2019-08-22       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.